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Abstract: Breast cancer is the most common cancer among women and the molecular pathways that play main roles in breast cancer
regulation are still not completely understood. MicroRNAs (miRNAs) and transcription factors (TFs) are important regulators of gene
expression. It is important to unravel the relation of TFs, miRNAs, and their targets within regulatory networks to clarify the processes
that cause breast cancer and the progression of it. In this study, mRNA and miRNA expression studies including breast tumors and
normal samples were extracted from the GEO microarray database. Two independent mRNA studies and a miRNA study were selected
and reanalyzed. Differentially expressed (DE) mRNAs and miRNAs between breast tumor and normal samples were listed by using BRBArray Tools. CircuitsDB2 analysis conducted with DE miRNAs and mRNAs resulted in 3 significant circuits that are SOX10- and hsamiR-301a-dependent. The following significant circuits were characterized and validated bioinformatically by using web-based tools:
SOX10→hsa-miR-301a→HOXA3, SOX10→hsa-miR-301a→KIT, and SOX10→hsa-miR-301a→NFIB. It can be concluded that regulatory
motifs involving miRNAs and TFs may be useful for understanding breast cancer regulation and for predicting new biomarkers.
Key words: Breast cancer, miRNA, mRNA, transcription factor, regulatory circuits

1. Introduction
Breast cancer is a complex genetic disorder that is not
controlled by a single factor but is rather controlled by
many factors (http://www.cancer.org/). Although many
factors (genes, microRNAs (miRNAs), transcription
factors, etc.) that cause breast cancer and play a role in its
development have been identified with the advancement of
high-throughput technologies, the molecular mechanisms
playing a role in disease regulation have still not been
revealed. For this reason, it is important and inevitable
to identify the regulatory circuits and networks that will
explain the development and progression of breast cancer.
Gene expression regulation is an important
mechanism for controlling biological processes in the
cell. Transcriptional factors (TFs) are the regulators that
function at the transcriptional level, while miRNAs work
at the posttranscriptional level. In view of the fact that the
transcription of mRNA and miRNAs is controlled by TFs
and the expression of TFs is regulated by miRNAs, these
two important mechanisms cannot be separated from each
other. Therefore, characterization of these combinatorial
regulatory mechanisms is important to reveal the
biological processes that take part in breast cancer in detail
by constructing networks and circuits.
* Correspondence: gurbala@yahoo.com

miRNAs are small, noncoding RNA molecules that
regulate gene expression in posttranscriptional stages
(Lagos-Quintana et al., 2001; Lee and Ambros, 2001).
miRNAs play important roles in biological processes
such as development, cell division, cell differentiation,
and programmed cell death. In this context, it is possible
that altered miRNA expression may contribute to the
development and progression of diseases such as cancer.
The presence of abnormal miRNA expression profiling
in many diseases, including breast cancer, has been
demonstrated and validated by intensifying miRNA
studies (Iorio et al., 2005; Lowery et al., 2009; Enerly et
al., 2011; Romero-Cordoba et al., 2012). The finding that
miRNA expressions are often dysregulated in cancers has
made these molecules important candidates for cancer
markers (Calin et al., 2002; Lu et al., 2005). Therefore, the
search for the relationship of miRNAs with target genes
(this may be an mRNA or a TF) has great importance for
the diagnosis and treatment of breast cancer.
TFs are essential regulatory elements in the
transcriptional pathway, which work by binding to target
genes that have specific DNA sequences, usually in the
promoter region (Latchman, 1997). TFs regulate their
targets at the transcription level by inhibiting or enhancing
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their expression while miRNAs regulate target mRNAs
at the posttranscriptional level in the form of inhibition.
miRNAs also undergo the transcription process and they
regulate their target genes like TFs. When all these reasons
are taken into consideration:
· Expression of a miRNA may be regulated by a
transcription factor;
· Expression of a TF may be regulated by a miRNA;
· Similarly, the transcription factor and miRNA may
regulate the expression of target genes together.
In recent years, many researchers have been working
on TFs, miRNAs, and their regulation mechanism on
posttranscriptional and transcriptional levels. With
the help of system biology approaches, transcription
factor-miRNA-target gene relationships were started to
be explored by an increasing number of studies. These
studies have mostly used and/or developed bioinformatics
and statistical methods and they have reviewed the
existing information. The tools that analyze miRNA-TF
relationships can be grouped into three subgroups. The
tools in the first group are intended to analyze statistically
the gene clusters organized by cooperating miRNAs and/
or miRNAs using matched miRNA and mRNA expression
profiles (Yoon and De Micheli, 2005; Joung et al., 2007;
Tran et al., 2008; Joung and Fei, 2009; Nam et al., 2009). The
tools in the second group again predict gene expression
relationships using gene expression data (Naeem et al.,
2011). The tools in the third group provide static circuits,
combining statistical data obtained from literature (e.g.,
CircuitDB) (Friard et al., 2010b).
In light of the above mentioned information, this work
aims to identify breast cancer-specific miRNA-TF-mRNA
circuits bioinformatically that could be important in breast
cancer development. We have identified regulatory circuits
and molecule associations that differ between the normal
group and breast cancer patients by using previously
performed expression studies.
2. Materials and methods
2.1. Selection of miRNA and mRNA microarray studies
It was aimed to obtain miRNA and mRNA microarray data
related to breast cancer in the literature. GEO, a publicly

available database at http://www.ncbi.nlm.nih.gov/geo/
(Edgar et al., 2002), was used for this purpose. “miRNA
/ mRNA”, “microarray”, and “breast cancer” terms were
used together when searching in GEO. The datasets were
selected from among the ones that have freshly frozen
tumor and normal tissue information. Microarray data
obtained from blood samples, formalin-fixed paraffinembedded tissues, and cell lines were excluded from the
study to prevent biased expression profiles.
As a result, 2 independent mRNA studies and 1 miRNA
study including breast tumors and normal samples were
selected to be analyzed (Table 1).
2.2. Class comparison analysis
The raw data were obtained from the microarray database
(GEO) and normalized by using quantile normalization
in BRB-Array Tools, which is an Excel-integrated
package for the visualization and statistical analysis of
microarray gene expression data. Quantile normalization,
one of the most widely adopted methods for analyzing
microarray data, was used as the normalization method.
Normalization is important to remove any differences
that may arise from technical problems and to make the
data comparable. Class comparison tests were performed
to find out differentially expressed miRNAs and mRNAs
between tumor samples and normal samples (P ≤ 0.05,
2-fold change). This test provides powerful methods for
finding differentially expressed genes when controlling
the ratio of false positives. Differentially expressed and
common genes (by Venny 2.1.0) were found for tumor
vs. normal comparison in GSE3744 and GSE5764 (http://
bioinfogp.cnb.csic.es/tools/venny_old/venny.php). Lastly,
differentially expressed miRNAs were found in GSE45666.
2.3. Identification of TFs in DE mRNA lists
Transcription factor lists that have been identified in
the human body were accessed by using the Animal
Transcription Factor DataBase 2.0 (http://www.bioguo.
org/AnimalTFDB/) (Zhang et al., 2015) and the TFs that
were in the DE genes were determined by comparison
with these lists.
2.4. Circuit analysis
The CircuitsDB2 analysis tool was used to identify the
breast cancer-specific circuits as regulatory loops among

Table 1. The characteristics of the datasets.
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GEO ID

Platform

Normal samples

Tumor samples

GSE3744

Affymetrix Human Genome U133 Plus 2.0 Array

7

40

GSE5764

Affymetrix Human Genome U133 Plus 2.0 Array

15

15

GSE45666
GSE17907
(Test data)

Agilent-021827 Human miRNA Microarray G4470C

15

80

Affymetrix Human Genome U133 Plus 2.0 Array

4

51
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the members of DE miRNAs, mRNAs, and TFs. This userfriendly tool provides static circuits by combining statistical
data obtained from the literature. It contains precompiled
transcriptional and posttranscriptional networks, the sets
of network motifs, and series of functional and biological
information, which are based on JASPAR DB and the
ENCODE project. Members of the DE miRNAs, mRNAs,
and TFs were searched in microRNA-mediated FFLs in
which a TF is the master regulator in CircuitsDB2 (Friard
et al., 2010b).
2.5. Circuit member analysis in diseases, biological
processes, and pathways
For the characterization of the members of the significant
circuits three different tools, PhenomiR, WebGeshtalt, and
DIANA, were used.
The PhenomiR 2.0 database, completely generated by
manual curation of experienced annotators, was used to
obtain information about differentially regulated miRNA
(circuit member miRNA, hsa-miR-301a here) expression
in diseases (breast cancer here) (Ruepp et al., 2010).
WebGestalt is the “WEB-based GEne SeT AnaLysis
Toolkit”, in which the functional genomic, proteomic,
and large-scale genetic studies from large numbers of
gene lists (e.g., DE gene list) are continuously generated.
Function analysis of the circuit member genes and TFs
was performed with the WebGestalt Protein Interaction
Network Module (Wang et al., 2013).
DIANA-mirPath v.3 was used to search the pathways
of circuit member miRNA. It is a miRNA analysis tool that
enables users to find targets of mRNAs by using different
algorithms and to find pathways in which these genes are
significantly enriched (Maragkakis et al., 2009; Vlachos et
al., 2015).
2.6. Validation analysis
For advanced bioinformatics analysis for in silico validation
of significant circuits, the mirExTra 2.0 under DIANA was
used. Our miRNA and mRNA lists were analyzed using
the Central microRNA Discovery Module (CmD) and
miRNA-mRNA relationships in the circuits were tried to
be validated. This module combines microRNA and mRNA
expression data results (names, P-values, fold changes)
in order to identify functional microRNAs responsible
for changes in mRNA expression by utilizing in silico
interactions from DIANA-microT-CDS. In this study, DE
miRNA and mRNA lists were used for mirExtra analysis. It
enabled us to determine the central regulator miRNAs and
their targets and provided us the opportunity to validate
our results (Maragkakis et al., 2009; Vlachos et al., 2016).
3. Results
3.1. The miRNA and mRNA datasets
The miRNA microarray studies and mRNA microarray
studies were searched to find differentially expressed

miRNAs and mRNAs between breast cancer and normal
tissues. Three independent microarray datasets were
obtained from GEO (http://www.ncbi.nlm.nih.gov/geo/)
(Edgar et al., 2002).
One of the datasets was a miRNA microarray study
performed with 80 breast cancer samples and 15 normal
samples (GSE45666 (Lee et al., 2013)). Two of the datasets
were mRNA microarray studies (GSE3744 (Richardson
et al., 2006), GSE5764 (Turashvili et al., 2007)). The total
number of breast cancer samples and normal samples were
55 and 22, respectively. The details of the platforms and the
sample numbers are given in Table 1.
3.2. Differentially expressed miRNA and mRNA lists
The miRNA microarray study and two mRNA studies
(Table 1) were independently analyzed by BRB-Array
Tools, which is an integrated package for the visualization
and statistical analysis of gene expression data (Simon
et al., 2007). Quantile normalization was used as the
normalization method. All studies consisted of 2 groups,
which are tumor and normal. Class comparison tests were
performed to find out differentially expressed miRNAs
and mRNAs between tumor and normal samples. This
test provides powerful methods for finding differentially
expressed genes when controlling the ratio of false
positives. This method is similar to the significance
analysis of microarrays method (Tusher et al., 2001) but
provides more control of the false discovery rate (Simon
et al., 2007).
As a result of class comparison analysis, miRNA and
mRNA lists were obtained. Twenty-three miRNAs (11
upregulated and 12 downregulated; Table S1) were found
to be differentially expressed between tumor and normal
samples. Since two mRNA studies were performed, the DE
mRNAs were listed as common DE genes in both of the
studies. A total of 264 mRNAs (187 downregulated and
77 upregulated; Table S1) were found to be differentially
expressed between tumor and normal samples and were
common for each mRNA study.
3.3. Differentially expressed transcription factors list
To obtain the TFs among DE mRNA lists, which are given
in Table S1, AnimalTFDB 2.0 was used (Zhang et al., 2015).
This tool has a dataset that consists of 1691 transcription
factors in 68 families in humans. When we compared it to
the DE list, 18 of the genes in the DE gene list were found
to encode proteins functioning as TFs: ATF3, BHLHE41,
EHF, FOSB, HOXA3, ID4, IRX1, NFIB, SOX10, MAFF,
FOS, NR3C2, STAT1, EGR1, JUN, ZNF662, THRB, and
ZBTB16.
3.4. Significant breast cancer-specific circuits
CircuitsDB2 was used to identify important and regulatory
circuits that consist of the members of DE miRNA, mRNA,
and TF lists. CircuitsDB2 is a web service that includes
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data as regulatory loops stored in a relational database that
can be accessed through a dynamic web interface (Friard
et al., 2010b). With use of this interface it is possible to find
different kinds of circuits like feedforward loops (FFLs)
in which a TF regulates a miRNA and they both regulate
a target gene (Friard et al., 2010a). Members of the DE
miRNA, mRNA, and TF lists were searched in microRNAmediated FFLs in which a TF is the master regulator in
CircuitsDB2.
Three significant circuits that are SOX10- and hsamiR-301a-dependent were identified (Figure 1a) by
CircuitsDB2 [5] analysis; in each circuit, hsa-miR-301a
was found to be upregulated and its TF target SOX-10 was
downregulated. Additionally, the three target genes that
were under regulation of both miR-301a and SOX10 were
downregulated as expected (Figure 1b).
3.5. Circuit members in diseases, biological processes,
and pathways
To characterize the significant circuits in detail, their
presence in diseases, biological processes, and signaling
pathways were identified in detail by using related webbased tools.

The first step was to search the expression information
of miRNA hsa-miR-301a. When breast cancer association
data were extracted, concordant with our finding, it was
found to be overexpressed in breast tumors. Since the data
in PhenomiR (Ruepp et al., 2010) were obtained from
independent studies and contain results from both cell
lines and tumor samples, our results related to hsa-miR301a could be accepted as robust for breast cancer (Table
2). Given the pathological, histological, and molecular
differences (e.g., MCF-7: ER+; SK-BR-3: HER2+; MDAMB-231: triple-negative) of the cell lines in Table 2, hsamiR-301a, which is upregulated in the different cell lines
and tumor specimens, may be accepted as a generalized
and important marker for breast cancer. Additionally
the expression profiles of other members of the circuits,
SOX10, HOXA3, KIT, and NFIB, were searched in an
independent microarray dataset (GSE17907; 51 tumor
and 4 normal breast samples) and compatible to our
results found to be significantly downregulated in tumor
samples compared to normal ones (SOX10, P-value 1.00E07, 11-fold downregulation; HOXA3, P-value 0.0004616,
4-fold downregulation; KIT, P-value, 3.00E-07, 11-fold

Figure 1. Significant circuits, which were results of CircuitsDB2 analysis. a) The triangular shapes are circuit diagrams taken from
CircuitsDB2. The dark blue circles represent the TF, the green circles represent the miRNA, and the light blue circles represent the
targets. b) Downregulation and upregulation terms indicate the differentiation of expression according to tumor vs. normal.
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Table 2. Expression changes of hsa-miR-301a in previous studies in the literature. The table was created with the information obtained
from PhenomiR 2.0 (Ruepp et al., 2010).
No.

ID

miRNA name

Disease

Tissue/cell line

PubMed ID

Regulation

Study design

1

447

hsa-mir-301a

Breast
cancer

Breast epithelium

16754881

Up

Patient study,
phenotype-control

2

451

hsa-mir-301a

Breast
cancer

MCF-7 cell

16192569

Up

Cell culture study

3

366

hsa-mir-301a

Breast
cancer

T-47D cell

16192569

Up

Cell culture study

4

481

hsa-mir-301a

Breast
cancer

MDA-MB-231 cell

16192569

Up

Cell culture study

5

377

hsa-mir-301a

Breast
cancer

SK-BR-3 cell

16192569

Up

Cell culture study

6

482

hsa-mir-301a

Breast
cancer

MDA-MB-361 cell

16192569

Up

Cell culture study

downregulation; and NFIB, P-value 0.0012966, 3.7-fold
downregulation).
The second step was to find out the pathways in which
the targets of hsa-miR-301a were taking part. DIANAmirPath v.3 was used for this purpose (Maragkakis et
al., 2009; Vlachos et al., 2015). This tool aims to find the
targets of microRNAs by using 3 different target algorithms
(TargetScan, microT-CDS, and Tarbase) and determining
the pathways in which these genes are significantly
enriched. The members of our circuits, KIT, NFIB, and
HOXA3, were among the identified targets (by mirPath)
of hsa-miR-301a (data not shown). It was also seen in the
HeatMap plotted after the pathway analysis that the targets
of this microRNA function in pathways that are known to
be important in cancer (Figure 2).
The third step was function analysis of the genes. For
the characterization of the members of the significant
circuits, which are SOX10, KIT, NFIB, and HOXA3,
function analysis was performed for each of them using
WebGestalt protein interaction network module-related
function analysis (Table 3) (Wang et al., 2013).
3.6. Advanced bioinformatics analysis for in silico
validation
To validate the significant circuits, the DIANA-mirExTra
2.0 tool was used (Maragkakis et al., 2009; Vlachos et
al., 2016). We used DE miRNA and mRNA lists with
fold change and P-value information as an input and
the algorithm identified which miRNAs were central
regulators (interactions based on microT-CDS and
threshold type based on fold change with 2-fold change).
Analysis showed that the most regulatory upregulated
(tumor vs. normal) miRNA was hsa-miR-301a (P = 7.3e-

03), while the most regulatory downregulated (tumor vs.
normal) miRNA was hsa-miR-376c (P = 6.4e-03), which is
also the most downregulated DE miRNA in our list. As can
be seen in Figure 3, hsa-miR-301a, which is the regulatory
miRNA of the 3 circuits (Figure 1), was expressed as one of
the central miRNAs, and as can be seen in the interaction
details, KIT, NFIB, and HOXA3 are among the regulated
target genes (Figure 3). These advanced and independent
analysis results confirm and validate our CircuitsDB2
circuit analysis results.
4. Discussion
Breast cancer is a complex genetic disorder that is not
controlled by a single factor but is controlled by many
variables and is still the most common type of cancer in
women today (http://www.cancer.org/). Although many
scientific studies have been carried out on breast cancer,
it is still unclear in many respects. Since breast cancer is a
complex disease, to understand the development of breast
cancer new biomarkers need to be discovered. In addition
to the discovery of new biomarkers, it is also of great
importance to investigate their relationships with each
other (e.g., miRNA-TF-mRNA circuits). In recent years,
systems biology approaches have become more important
in the understanding of diseases. The development of the
methods that help to understand large molecular data and
the molecular mechanisms of breast cancer development
is inevitable.
The aim of this study was to analyze the TF-miRNAtarget gene relationships in a global perspective in breast
cancer samples and to determine miRNA-TF-mRNA
circuits that can play a role in breast cancer.
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Figure 2. Pathway enrichment results of hsa-miR-301a targets. Targets of the miRNA and
KEGG pathway results were used to construct the heat map, which was obtained from DIANA
(Maragkakis et al., 2009; Vlachos et al., 2015). The intensity of color represents the logarithmic
P-values.

Table 3. Function analysis results for the members of the significant circuits. The table was created with the information
obtained from the WebGestalt protein interaction network module and related function analysis (Wang et al., 2013).
Gene name

SOX10

Biological process

Cellular component

Molecular function

Positive regulation of

Extrinsic to mitochondrial

HMG box domain

gliogenesis

outer membrane

binding

P = 4.84e-07

P = 9.81e-04

P = 1.91e-11

Intracellular signal
KIT

transduction
P = 4.67e-10
Anterior/posterior pattern

NFIB

specification
P = 0e+00
Negative regulation of

HOXA3

DNA replication
P = 1.54e-03

108

Cytosol
P = 3.22e-06
Nucleus
P = 0e+00
Perinuclear theca
P = 3.36e-03

Signaling adaptor
activity
P = 1.07e-09
Sequence-specific DNA
binding
P = 0e+00
Biotin-[acetyl-CoA-carboxylase]
ligase activity
P = 2.03e-03

ÖZTEMUR ISLAKOĞLU et al. / Turk J Biol

Figure 3. Validation results of the circuits members. hsa-miR-301a (upregulated) and hsa-miR-376c (downregulated) are the central
regulator miRNAs for the tumor vs. normal comparison. KIT and NFIB are targeted by hsa-miR-301a and hsa-miR-376c while HOXA3
is targeted by only hsa-miR-301a. The figure was obtained from DIANA-mirExTra 2.0 (Maragkakis et al., 2009; Vlachos et al., 2016).
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In this study we focused on finding out regulatory
miRNA-TF-mRNA circuits specific to breast cancer
with the help of various web-based tools and databases.
Through the workflow designed in the study and the
bioinformatics methods used, three independent
microarray studies (Table 1) were reanalyzed and were
converted to circuits that are important in breast cancer
development. The whole process enabled us to make
more use of the data in the literature, which was achieved
by using a microarray that is a high-throughput and
expensive method. The tools used in the workflow are not
only used to cross-check the data but also to validate the
robustness of the results of this work. Such a work flow
can also be applied for other diseases (Figure 4).
Circuit analysis revealed 3 significant miRNA-TFmRNA circuits that are SOX10- and hsa-miR-301adependent: SOX10→hsa-miR-301a→HOXA3, SOX10→hsamiR-301a→KIT,
and
SOX10→hsa-miR-301a→NFIB
(Figure 1a). hsa-miR-301a, the common member of the
circuits, is known to be an important miRNA in breast

cancer. It was found to be upregulated in breast tumors for
our circuits (Figure 1b). In 2011, it was reported as a novel
oncogene in lymph node-negative breast cancer and it was
shown to mediate proliferation, migration, and invasion
(Shi et al., 2011). Since then, other studies have been
performed regarding the role of miR-301a upregulation
in breast cancer (Ma et al., 2014; McDermott et al.,
2014). In 2014, upregulation of that miRNA was found
to be associated with poor prognosis in triple-negative
breast cancers (Yu et al., 2014). When we searched the
expression information of miRNA in PhenomiR (Ruepp
et al., 2010), it was found to be overexpressed in breast
tumors in independent studies (Table 2). Considering
the concordance of the literature with our results and the
pathological, histological, and molecular variability (e.g.,
ER+, HER2+, triple-negative) of the samples in Table 2
and in the literature, hsa-miR-301a, which is consistently
upregulated in different breast cancer cell lines and
tumors, may be accepted as a generalized marker for
breast cancer development.

Figure 4. General study design and workflow. Purple boxes represent bioinformatics tools used for the processing of the data, green
boxes represent main work steps, and orange ellipses represent input and outputs.
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The results of DIANA-mirPath together with
WebGestalt may strengthen the role of these significant
circuits in breast cancer. The pathway enrichment analysis
results showed that the target genes and the target TF SOX10
were found to be members of cancer-specific pathways like
TGF-beta, mTOR, and p53 signaling pathways. SOX10,
which is the common TF in our circuits, was reported to
be one of the regulated TFs in breast cancer by Zang et
al. Those authors combined seven studies that conducted
next-generation sequencing for breast tumors and normal
samples and, concordant with our in silico results, SOX10
was found to be downregulated in breast cancers (Zang et
al., 2017).
The two common members of the three circuits in this
study are two regulative elements of gene regulation, a
miRNA and a TF. The balance of the reciprocal regulation
among these two important elements may determine
the fate of the cell, which is in our situation cancer
progression. In the suggested circuits in this study the
regulative effect of miRNA is seen to be dominant and it

is consistently upregulated and negatively regulates the TF
(SOX10) expression. This tight regulation among miRNATF affected the cancer-related target genes HOXA3, KIT,
and NFIB. The well-known regulation of these target
genes in different cancers (Moon et al., 2011; Jachetti et
al., 2017; Zhang et al., 2017) and validation of them to be
downregulated in breast tumor samples by an independent
microarray dataset support the idea of the systems biology
approach in cancers originating from different tissues.
In summary, the results of this study show that
regulatory motifs involving miRNAs and TFs may be
useful for understanding breast cancer regulation and
for predicting new biomarkers. Characterization of these
combinatorial regulatory mechanisms is important to
reveal the biological processes that take part in breast
cancer in detail by constructing networks and circuits.
Finding out new circuits combining miRNAs, TFs, and
mRNAs may provide further insight to improve our
knowledge of breast cancer development.
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Table S1. Differentially expressed gene and miRNA lists.
Common elements in “GSE5764” and “GSE3744” (upregulated common genes)
Gene Symbol

GeneBank ID

Gene Name

COL10A1

AI376003

collagen, type X, alpha 1

COL11A1

NM_001854

collagen, type XI, alpha 1

COL1A2

AA788711

collagen, type I, alpha 2

COL1A1

BE221212

collagen, type I, alpha 1

COL5A2

AL575735

collagen, type V, alpha 2

BGN

BC002416

biglycan

INHBA

NM_002192

inhibin, beta A

CTHRC1

AA584310

collagen triple helix repeat containing 1

LRRC15

NM_130830

leucine rich repeat containing 15

HSD17B6

NM_003725

hydroxysteroid (17-beta) dehydrogenase 6 homolog (mouse)

WISP1

NM_003882

WNT1 inducible signaling pathway protein 1

SULF1

AW043713

sulfatase 1

MMP11

AI761713

matrix metallopeptidase 11 (stromelysin 3)

GMFB

BC005359

glia maturation factor, beta

FN1

W73431

fibronectin 1

FNDC1

AI345957

fibronectin type III domain containing 1

COMP

NM_000095

cartilage oligomeric matrix protein

TRIM59

N90779

tripartite motif containing 59

CXCL10

NM_001565

chemokine (C-X-C motif) ligand 10

COL8A1

BE877796

collagen, type VIII, alpha 1

CCNB2

NM_004701

cyclin B2

GPRC5A

NM_003979

G protein-coupled receptor, family C, group 5, member A

HMMR

NM_012485

hyaluronan-mediated motility receptor (RHAMM)

ASPM

NM_018123

asp (abnormal spindle) homolog, microcephaly associated (Drosophila)

POLE2

NM_002692

polymerase (DNA directed), epsilon 2, accessory subunit

MKI67

AU152107

antigen identified by monoclonal antibody Ki-67

ATP6V1C1

AW024925

ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C1

MCM6

NM_005915

minichromosome maintenance complex component 6

IFI44

BE049439

interferon-induced protein 44

IFI6

NM_022873

interferon, alpha-inducible protein 6

ISG15

NM_005101

ISG15 ubiquitin-like modifier

STAT1

NM_007315

signal transducer and activator of transcription 1, 91kDa

TP53RK

BG339450

TP53 regulating kinase

KIAA0101

NM_014736

KIAA0101

LYZ

U25677

lysozyme

GNA13

NM_006572

guanine nucleotide binding protein (G protein), alpha 13

CENPF

NM_016343

centromere protein F, 350/400kDa (mitosin)

OAS1

NM_016816

2’-5’-oligoadenylate synthetase 1, 40/46kDa

NEK2

NM_002497

NIMA (never in mitosis gene a)-related kinase 2

RAB2A

AA535244

RAB2A, member RAS oncogene family

NCAPG

NM_022346

non-SMC condensin I complex, subunit G
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KIF15

NM_020242

kinesin family member 15

SMC2

NM_006444

structural maintenance of chromosomes 2

PRR11

NM_018304

proline rich 11

BUB1

AF043294

budding uninhibited by benzimidazoles 1 homolog (yeast)

NUSAP1

NM_016359

nucleolar and spindle associated protein 1

MLF1IP

MLF1 interacting protein

TYMS

AB077208

thymidylate synthetase

MRPL15

NM_014175

mitochondrial ribosomal protein L15

TOP2A

AU159942

topoisomerase (DNA) II alpha 170kDa

SKA2

BG496998

spindle and kinetochore associated complex subunit 2

CXCL11

AF030514

chemokine (C-X-C motif) ligand 11

DCBLD1

NM_173674

discoidin, CUB and LCCL domain containing 1

GJB2

M86849

gap junction protein, beta 2, 26kDa

IFI27

NM_005532

interferon, alpha-inducible protein 27

TACC3

NM_006342

transforming, acidic coiled-coil containing protein 3

DTL

NM_016448

denticleless E3 ubiquitin protein ligase homolog (Drosophila)

PNP

NM_000270

purine nucleoside phosphorylase

DHX9

NM_001357

DEAH (Asp-Glu-Ala-His) box polypeptide 9

CCNE2

NM_004702

cyclin E2

PRC1

NM_003981

protein regulator of cytokinesis 1

SMC4

NM_005496

structural maintenance of chromosomes 4

IFIT1

NM_001548

interferon-induced protein with tetratricopeptide repeats 1

SQLE

BU754109

squalene epoxidase

CCDC109B

NM_017918

coiled-coil domain containing 109B

ZWINT

NM_007057

ZW10 interactor

EZH2

NM_004456

enhancer of zeste homolog 2 (Drosophila)

CDKN3

AF213040

cyclin-dependent kinase inhibitor 3

CCNB1

BE407516

cyclin B1

TPX2

AF098158

TPX2, microtubule-associated, homolog (Xenopus laevis)

RSAD2

AI337069

radical S-adenosyl methionine domain containing 2

FBXO28

AU154086

F-box protein 28

MAD2L1

AF394735

MAD2 mitotic arrest deficient-like 1 (yeast)

SMC6

NM_024624

structural maintenance of chromosomes 6

LRR1

AA742244

leucine rich repeat protein 1

RACGAP1

AU153848

Rac GTPase activating protein 1

RRM2

BE966236

ribonucleotide reductase M2

KRT14

BC002690

keratin 14

PI15

NM_015886

peptidase inhibitor 15

SYNM

AK026420

synemin, intermediate filament protein

CNN1

NM_001299

calponin 1, basic, smooth muscle

KRT5

NM_000424

keratin 5

ACTG2

NM_001615

actin, gamma 2, smooth muscle, enteric

MYLK

AL832211

myosin light chain kinase
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SERPINB5

BC020713

serpin peptidase inhibitor, clade B (ovalbumin), member 5

LAMB3

L25541

laminin, beta 3

TRIM29

NM_012101

tripartite motif containing 29

SFRP1

AI332407

secreted frizzled-related protein 1

ID4

AW157094

inhibitor of DNA binding 4, dominant negative helix-loop-helix protein

IFFO2

AK024480

intermediate filament family orphan 2

MYH11

BF510409

myosin, heavy chain 11, smooth muscle

TAGLN

BC010946

transgelin

CX3CL1

NM_002996

chemokine (C-X3-C motif) ligand 1

MIR205HG

AI375939

MIR205 host gene (non-protein coding)

EGFR

AF277897

epidermal growth factor receptor

IRX1

AI870306

iroquois homeobox 1

NDRG2

NM_016250

NDRG family member 2

DAB2IP

AB051530

DAB2 interacting protein

FBXO2

NM_012168

F-box protein 2

KRT15

NM_002275

keratin 15

NFIB

AI700518

nuclear factor I/B

ANG

NM_001145

angiogenin, ribonuclease, RNase A family, 5

MYBPC1

BF593509

myosin binding protein C, slow type

ANXA3

M63310

annexin A3

MIR143HG

AL703532

MIR143 host gene (non-protein coding)

AK5

NM_012093

adenylate kinase 5

ST5

NM_005418

suppression of tumorigenicity 5

C2orf40

AF325503

chromosome 2 open reading frame 40

WLS

AA775681

wntless homolog (Drosophila)

CSRP1

NM_004078

cysteine and glycine-rich protein 1

COL17A1

NM_000494

collagen, type XVII, alpha 1

PTN

NM_002825

pleiotrophin

ACTA2

NM_001613

actin, alpha 2, smooth muscle, aorta

PDLIM3

AF002280

PDZ and LIM domain 3

CAB39L

NM_030925

calcium binding protein 39-like

MME

AI433463

membrane metallo-endopeptidase

CCL28

AF110384

chemokine (C-C motif) ligand 28

KLK7

NM_005046

kallikrein-related peptidase 7

MET

BG170541

met proto-oncogene (hepatocyte growth factor receptor)

INHBB

NM_002193

inhibin, beta B

LOC284454

BU617052

uncharacterized LOC284454

PIGR

NM_002644

polymeric immunoglobulin receptor

ZBTB16

NM_006006

zinc finger and BTB domain containing 16

FAM189A2

AA524029

family with sequence similarity 189, member A2

ECHDC2

NM_018281

enoyl CoA hydratase domain containing 2

ZNF395

NM_017606

zinc finger protein 395

OXTR

NM_000916

oxytocin receptor
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MGP

NM_000900

matrix Gla protein

TGFB1I1

BC001830

transforming growth factor beta 1 induced transcript 1

ATF3

AB078026

activating transcription factor 3

NEDD4L

AI357376

neural precursor cell expressed, developmentally down-regulated 4-like, E3 ubiquitin protein ligase

KIAA1217

BC018764

KIAA1217

C16orf89

AI823572

chromosome 16 open reading frame 89

SERPINA1

NM_000295

serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1

SOX10

AI367319

SRY (sex determining region Y)-box 10

MUCL1

NM_058173

mucin-like 1

SOCS2

AB004903

suppressor of cytokine signaling 2

ANXA1

NM_000700

annexin A1

CHPT1

AK025141

choline phosphotransferase 1

ITGB4

BF305661

integrin, beta 4

KIT

NM_000222

v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog

LOC100506990

AW192692

uncharacterized LOC100506990

TF

NM_001063

transferrin

EHF

NM_012153

ets homologous factor

SAV1

NM_021818

salvador homolog 1 (Drosophila)

SLC27A6

NM_014031

solute carrier family 27 (fatty acid transporter), member 6

RCAN1

NM_004414

regulator of calcineurin 1

GPM6B

AI419030

glycoprotein M6B

DCDC2

AW444617

doublecortin domain containing 2

ARHGEF28

BC012946

Rho guanine nucleotide exchange factor (GEF) 28

FOLR1

NM_016725

folate receptor 1 (adult)

CLDN8

AL049977

claudin 8

FTO

U79260

fat mass and obesity associated

PTPN14

NM_005401

protein tyrosine phosphatase, non-receptor type 14

ADAMTS5

BI254089

ADAM metallopeptidase with thrombospondin type 1 motif, 5

CGNL1

BC015433

cingulin-like 1

DMKN

AA706316

dermokine

BBOX1

NM_003986

butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) 1

PLAT

NM_000930

plasminogen activator, tissue

AZGP1

D90427

alpha-2-glycoprotein 1, zinc-binding

SIK3

BC035583

SIK family kinase 3

CMYA5

AL359338

cardiomyopathy associated 5

PDZK1

NM_002614

PDZ domain containing 1

C1orf168

AI076431

chromosome 1 open reading frame 168

LAMA3

AL708055

laminin, alpha 3

CD59

BF983379

CD59 molecule, complement regulatory protein

FOSB

NM_006732

FBJ murine osteosarcoma viral oncogene homolog B

SNX1

NM_003099

sorting nexin 1

FMO2

BC005894

flavin containing monooxygenase 2 (non-functional)

KIAA1683

AL136867

KIAA1683
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DUSP4

NM_001394

dual specificity phosphatase 4

ABCA5

BF693921

ATP-binding cassette, sub-family A (ABC1), member 5

GRAMD3

AW575493

GRAM domain containing 3

PLA2R1

NM_007366

phospholipase A2 receptor 1, 180kDa

ITGA2

NM_002203

integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)

GRAMD2

AU158463

GRAM domain containing 2

GAS1

AW611727

growth arrest-specific 1

LYPD6

BF061375

LY6/PLAUR domain containing 6

SORBS2

AF396457

sorbin and SH3 domain containing 2

TFPI2

AL574096

tissue factor pathway inhibitor 2

TACSTD2

AI627697

tumor-associated calcium signal transducer 2

LMOD1

NM_012134

leiomodin 1 (smooth muscle)

IL20RA

NM_014432

interleukin 20 receptor, alpha

WIF1

NM_007191

WNT inhibitory factor 1

LONP2

AI971258

lon peptidase 2, peroxisomal

PHYHD1

AL545998

phytanoyl-CoA dioxygenase domain containing 1

USP31

BG778320

ubiquitin specific peptidase 31

RND3

BG054844

Rho family GTPase 3

DMD

NM_004010

dystrophin

FHOD3

NM_025135

formin homology 2 domain containing 3

PAMR1

AI671186

peptidase domain containing associated with muscle regeneration 1

CLMN

AW028110

calmin (calponin-like, transmembrane)

EMP1

BC017854

epithelial membrane protein 1

KIAA1324

AB037745

KIAA1324

CDH3

NM_001793

cadherin 3, type 1, P-cadherin (placental)

BHLHE41

BE857425

basic helix-loop-helix family, member e41

RASSF6

AW070877

Ras association (RalGDS/AF-6) domain family member 6

CYP4X1

AA557324

cytochrome P450, family 4, subfamily X, polypeptide 1

NTRK2

NM_006180

neurotrophic tyrosine kinase, receptor, type 2

CX3CR1

AI033393

chemokine (C-X3-C motif) receptor 1

THRB

NM_000461

thyroid hormone receptor, beta

MAFF

NM_012323

v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian)

MAOA

NM_000240

monoamine oxidase A

TSPAN5

AF065389

tetraspanin 5

ZNF662

BE671164

zinc finger protein 662

CAV1

NM_001753

caveolin 1, caveolae protein, 22kDa

SCGB2A2

NM_002411

secretoglobin, family 2A, member 2

CXCL14

NM_004887

chemokine (C-X-C motif) ligand 14

GSTT2

NM_000854

glutathione S-transferase theta 2

ARMCX4

NM_152583

armadillo repeat containing, X-linked 4

GPRC5B

AF202640

G protein-coupled receptor, family C, group 5, member B

MYL9

NM_006097

myosin, light chain 9, regulatory

CFI

BC020718

complement factor I
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SLC4A7

NM_003615

solute carrier family 4, sodium bicarbonate cotransporter, member 7

GPC3

L47125

glypican 3

AMIGO2

AC004010

adhesion molecule with Ig-like domain 2

PALMD

NM_017734

palmdelphin

CITED1

NM_004143

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 1

PTPN21

X79510

protein tyrosine phosphatase, non-receptor type 21

PDK4

AL832708

pyruvate dehydrogenase kinase, isozyme 4

RGS2

NM_002923

regulator of G-protein signaling 2, 24kDa

CAT

NM_001752

catalase

HSD17B2

NM_002153

hydroxysteroid (17-beta) dehydrogenase 2

HMGCS2

NM_005518

3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)

ISM1

AL133463

isthmin 1 homolog (zebrafish)

CLDN11

BC039437

claudin 11

FOS

BC004490

FBJ murine osteosarcoma viral oncogene homolog

VWA5A

NM_014622

von Willebrand factor A domain containing 5A

CAV2

BF197655

caveolin 2

SSPN

BC041929

sarcospan

MAMDC2

AI862120

MAM domain containing 2

JUN

BG491844

jun proto-oncogene

GFRA1

NM_005264

GDNF family receptor alpha 1

ANPEP

NM_001150

alanyl (membrane) aminopeptidase

N4BP2L1

AF113009

NEDD4 binding protein 2-like 1

TENM2

AB032953

Teneurin Transmembrane Protein 2

NOVA1

NM_002515

neuro-oncological ventral antigen 1

SCGB3A1

AA742697

secretoglobin, family 3A, member 1

FAM129A

NM_022083

family with sequence similarity 129, member A

STEAP4

NM_024636

STEAP family member 4

STC2

AI435828

stanniocalcin 2

USP47

BE966019

ubiquitin specific peptidase 47

CRYAB

AF007162

crystallin, alpha B

ZNF204P

AF033199

zinc finger protein 204, pseudogene

PNISR

AA902326

PNN-interacting serine/arginine-rich protein

EGR1

AV733950

early growth response 1

HOXA3

NM_030661

homeobox A3

FZD7

AI333651

frizzled family receptor 7

ALB

D16931

albumin

APOD

NM_001647

apolipoprotein D

PIP

NM_002652

prolactin-induced protein

SYNPO2

AW009747

synaptopodin 2

HIPK2

R37104

homeodomain interacting protein kinase 2

FAM126A

AB030241

family with sequence similarity 126, member A

SCUBE2

AI424243

signal peptide, CUB domain, EGF-like 2

CDC14B

NM_003671

CDC14 cell division cycle 14 homolog B (S. cerevisiae)
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TGFBR3

NM_003243

transforming growth factor, beta receptor III

ADD3

BE545756

adducin 3 (gamma)

TMX4

AL544094

thioredoxin-related transmembrane protein 4

TM4SF18

AI721164

transmembrane 4 L six family member 18

PLK2

NM_006622

polo-like kinase 2

CXCL2

BC005276

chemokine (C-X-C motif) ligand 2

NR3C2

NM_000901

nuclear receptor subfamily 3, group C, member 2

FMO5

BC020872

flavin containing monooxygenase 5

upregulated miRNAs
hsa-miR-720
hsa-miR-107
hsa-miR-96
hsa-miR-155
hsa-miR-181b
hsa-miR-1280
hsa-miR-484
hsa-miR-141
hsa-miR-362-3p
hsa-miR-301a
hsa-miR-375
downregulated miRNAs
hsa-miR-204
hsa-miR-139-5p
hsa-miR-551b
hsa-miR-10b*
hsa-miR-143
hsa-miR-145
hsa-miR-376c
hsa-miR-654-3p
hsa-miR-188-5p
hsa-miR-30a
hsa-miR-202
hsa-miR-135a
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